Associations - MLH1 (MutL homolog 1)

MLH1 mutation	Gastric Cancer	MLH1 mutation	Gastric Cancer	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2
MLH1 mutation	Gastric Cancer	MLH1 mutation	Gastric Cancer	durvalumab + tremelimumab-actl Sensitive: C2 – Inclusion Criteria durvalumab + tremelimumab-actl Sensitive : C2	durvalumab + tremelimumab-actl Sensitive: C2 – Inclusion Criteria durvalumab + tremelimumab-actl Sensitive : C2
MLH1 V384D	Non Small Cell Lung Cancer	MLH1 V384D	Non Small Cell Lung Cancer	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3
MLH1 V384D	Non Small Cell Lung Cancer	MLH1 V384D	Non Small Cell Lung Cancer	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3
MLH1 V384D	Non Small Cell Lung Cancer	MLH1 V384D	Non Small Cell Lung Cancer	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3
MLH1 deletion	Endometrial Adenocarcinoma	MLH1 deletion	Endometrial Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MLH1 deletion	Prostate Cancer	MLH1 deletion	Prostate Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Colorectal Cancer	MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Colorectal Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MSI-H/dMMR + MLH1 deletion	Colorectal Cancer	MSI-H/dMMR + MLH1 deletion	Colorectal Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MSI-H/dMMR + MLH1 deletion	Endometrial Cancer	MSI-H/dMMR + MLH1 deletion	Endometrial Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
MLH1 deletion+ PMS2 deletion	Endometrial Cancer	MLH1 deletion+ PMS2 deletion	Endometrial Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
MLH1 mutation	Prostate Cancer	MLH1 mutation	Prostate Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3

MLH1 (MutL homolog 1)

Associations(27)

Associations
(27)